Legal Questions Still Dogging Wyeth
Wyeth says little about hormone-replacement therapy litigation, except to give a tally of trial results and lawsuit filings in its quarterly reports to the SEC. By March 31, Wyeth was defending approximately 5,400 lawsuits affecting 7,900 plaintiffs. Wyeth said it doesn't have a litigation reserve because it cannot estimate the potential liability or know for sure if there is a liability.
Merrill Lynch analyst David Risinger recently told clients that Wyeth hasn't set aside a reserve because its $350 million insurance policy for the drugs hasn't been exhausted.
"When the company has run through that insurance, it will need to expense defense costs," he said in a June 23 report. Risinger, who has a buy rating, doesn't own shares. His firm says it expects to receive or seek investment-banking compensation from Wyeth in the near future.
Wyeth has won 22 of 27 cases thus far by jury verdict, summary judgment or voluntary dismissal by plaintiffs, according its latest SEC filing. All cases involved breast-cancer claims. Of the five losses, two cases were settled and two are being appealed. In one case, a judge ordered a new trial.Legal experts say an early victories by companies in product-liability suits discourage plaintiffs from filing weak cases while encouraging settlements. Merck is the prime exhibit for this strategy. Its fight-every-Vioxx-case approach and its ability to win more than it lost in early rounds led to a November agreement to settle most of the U.S. cases. Merck is paying $4.85 billion into a special fund, and it said it would contest other cases in court.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV